SLN.L Regulatory News (SLN)

Silence Therapeutics Notice of Annual General Meeting and publication of Annual Report

London, 7th March 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its annual report and financial statements for the year ended 31 December 2017 ("Annual Report and Accounts") is available for download on the Company's website www.silence-therapeutics.com. The Annual Report and Accounts will be posted to shareholders on 16 March 2018.

This year's Annual General Meeting ("AGM") of the Company will be held on 23 April 2018 at 10am. The Notice of the AGM will be posted to shareholders on or before 16 March 2018, when it will also be made available on the Company's website. The AGM will be held at the offices of Silence Therapeutics Plc, 72 Hammersmith Road, London, United Kingdom W14 8TH, and registration of attendees and the distribution of voting slips will commence at the meeting venue at 9.45am.

Enquiries:

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. For more information, please visit: http://www.silence-therapeutics.com/